Search

everythinglearnresearchcommunity

for

Search:↓

Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.

Non-white organ transplant patients have worse skin cancer outcomes due to later diagnosis and treatment.

Nonmelanoma skin cancers have higher levels of certain osteopontin variants than normal skin.

Non-melanoma skin cancer in darker-skinned people can be misdiagnosed, so doctors need to be more aware to diagnose it correctly and early.

5α-reductase inhibitors like Finasteride and Dutasteride may help manage prostate cancer by blocking testosterone conversion.

Reducing SOX2 in colorectal cancer cells decreases tumor growth and self-renewal.

Patients should discuss complementary medicine use with doctors to improve health outcomes.

Different prostate cancer treatments have similar risks of secondary cancers and related mortality when considering patient age and smoking history.

Finasteride for hair loss may increase the risk of certain cancers and has side effects; better regulation and education on its use are needed.

Age, race, family history, and certain genetic factors increase prostate cancer risk.

Birth control pills slightly increase the risk of breast cancer, especially if used before the first full-term pregnancy.

Stem cells play a key role in nonmelanoma skin cancers, with different origins and genetic changes linked to basal and squamous cell carcinomas.

Understanding breast cancer requires considering both medical advancements and social influences.

Chemotherapy-induced hair loss significantly affects patients' well-being, and nurses are key in helping them cope, but more research is needed to find effective treatments.

Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.

Nanoparticle systems make cancer treatment less toxic.

Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.

Core symptoms in breast cancer chemotherapy remain stable, aiding targeted interventions.

Wedelolactone may help prevent bone damage in breast cancer by blocking certain cell signals.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

Dietary phytoestrogens do not significantly affect testicular cancer risk.

Endocrine therapies for cancer significantly increase the risk of hair loss.

DMBT1 and galectin-3 may help suppress epithelial skin cancer.

Raman spectroscopy could effectively guide skin cancer surgery by identifying tumor margins.

Combining irinotecan and cetuximab is effective for some metastatic colorectal cancer patients but often causes manageable skin issues.

Using finasteride or dutasteride does not increase the risk of male breast cancer.

Some breast cancer patients developed permanent hair loss after chemotherapy and hormonal therapy, showing patterns similar to common baldness and alopecia areata.

Reduced sexual drive may be linked to male breast cancer, while anti-estrogenic factors might lower the risk.

Permanent hair dye use may increase bladder cancer risk, especially in female smokers with certain genetic traits.

X-ray diffraction of hair might help detect breast cancer non-invasively.